ArticleVeterinary and comparative oncology2026
The Definitive-Intent 10-Fraction Radiotherapy Protocol ('The Zurich Protocol') Yields Lasting Tumour Control and Survival in Dogs With Intracranial Meningiomas.
Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moderately hypofractionated definitive-intent radiotherapy protocols can be used for canine intracranial meningiomas to shorten overall treatment time while maintaining tumour control and limiting normal tissue toxicity. This retrospective study evaluated oncologic outcomes, toxicity, and radiation dose-volume-related prognostic factors in dogs with imaging-based intracranial meningiomas treated with a 10-fraction definitive-intent protocol. Medical records from 2015 to 2025 were reviewed. All dogs received 10 daily fractions of 4 Gy delivered with a homogeneous dose prescription, risk-adapted heterogeneous dose distributions, or an 11% simultaneously integrated boost (SIB) to the gross tumour volume. One hundred and ten dogs were included, with a median follow-up of 498 days. Median time to progression was 873 days (95% CI: 552-1195), median overall survival after first radiotherapy was 756 days (95% CI: 474-1039), and median DSS was 1078 days (95% CI: 915-1242). Time to progression differed among treatment subgroups (p = 0.024). Larger volumes of normal brain receiving ≥ 32 Gy (> 11.5 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.